- Trial Phase
- Approved (for actinic keratosis); sNDA under FDA review for superficial basal cell carcinoma
- Time to Market
- Already approved and marketed for actinic keratosis. The sBCC label-expansion decision is expected by September 28, 2026 PDUFA date.
- Why 8/10
- The next hard, dated catalyst is the FDA PDUFA target action date of September 28, 2026, for the sNDA seeking approval of Ameluz photodynamic therapy for superficial basal cell carcinoma (sBCC). This is ~2 weeks away and represents a major label-expansion decision for the company's lead commercial asset.
The PDUFA decision on Ameluz for sBCC on September 28, 2026 (~2 weeks away) is the dominant near-term catalyst for BFRI. The stock trades at ~$1.55 with a mean analyst target of $6 (287% implied upside). Approval would open a new indication market, while a CRL could pressure the stock given the ~$4.7M cash balance. Monitor the FDA decision date closely.
Price Chart
Executive Summary
Ameluz (aminolevulinic acid HCl gel / BF-200 ALA) is Biofrontera Inc.'s (Nasdaq: BFRI) lead commercial product — a topical photosensitizer used in photodynamic therapy (PDT) for dermatological conditions. It is already FDA-approved for actinic keratosis (AK) and generating growing revenue ($12M in Q2 2026, +33% YoY), with the company nearing cash-flow breakeven. The critical near-term catalyst is the FDA PDUFA date of September 28, 2026, for a supplemental NDA seeking approval for superficial basal cell carcinoma (sBCC). Analyst consensus is strongly bullish (7 Buy/Strong Buy vs 1 Hold) with a mean price target of $6, implying ~287% upside from the current ~$1.55 share price. Risks include limited cash ($4.7M), an ITC exclusion order on the companion RhodoLED lamp, and the binary nature of the pending FDA decision.
How It Works
Ameluz is a topical gel containing aminolevulinic acid (ALA), a photosensitizing agent. When applied to the skin and then activated by a specific red-light lamp (the RhodoLED), it generates a form of oxygen that selectively destroys abnormal skin cells while largely sparing healthy tissue. It is used in photodynamic therapy (PDT) for dermatological conditions like actinic keratosis (pre-cancerous sun-damaged skin lesions) and is being studied for superficial basal cell carcinoma (a common form of skin cancer).
Trial Status
Ameluz is already FDA-approved and commercially marketed for actinic keratosis (AK). A Phase 3 trial (NCT05662202) for field-directed AK treatment on extremities/neck/trunk was completed in 2025 with results. A Phase 2 trial (NCT05080764) for moderate-to-severe acne vulgaris was completed in January 2026. The sNDA for superficial basal cell carcinoma (sBCC) was accepted by the FDA with a PDUFA date of September 28, 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision on Ameluz sNDA for superficial basal cell carcinoma — September 28, 2026
- Potential Q3 2026 earnings report (timing TBD) — will show impact of ITC lamp exclusion order on revenue
- Phase 2 acne data readout — the Phase 2b trial for moderate-to-severe acne vulgaris was completed and positive results were announced in March 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Biofrontera Inc. 8-K BFRI ·Originating report